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A B S T R A C T
We generated eight induced pluripotent stem cell (iPSC) lines from Parkinson's disease (PD) patients with different familial mutations using non-integrating episomal
plasmids. All iPSC lines have a normal karyotype, express pluripotent genes including POU5F1, NANOG, and show alkaline phosphatase activity, as well as the ability
to differentiate into all three germ layers. These PD iPSC lines can be used for disease modeling to identify PD mechanisms and for the development or stratification of
new drugs.
Resource table
Unique stem cell lines
identifier
DANi-002C DANi-003H DANi-004A DANi-005A DANi-
006F DANi-007A DANi-008F DANi-009C
Alternative names of st-
em cell lines
GBA-002-C3 (DANi-002C) GBA-003-C8 (DANi-003H)
PRKN-004-C1 (DANi-004A) LRRK2-GBA-005-C1 (DANi-
005A) GBA-006-C6 (DANi-006F) PINK1-007-C1 (DANi-
007A) SNCA-008-C6 (DANi-008F) SNCA-009-C3 (DANi-
009C)
Institution Danish Research Institute of Translational Neuroscience
(DANDRITE), Aarhus, Denmark
Contact information of
distributor
Mark Denham, mden@dandrite.au.dk
Type of cell lines iPSC
Origin Human
Cell Source DANi002-DANi008: skin fibroblasts. DANi009: lympho-
blasts
Clonality Clonal
Method of reprogram-
ming
Non-integrating episomal vectors
Multiline rationale Same disease non-isogenic cell lines (Parkinson's disease
patients carrying different familial mutation)
Gene modification Yes
Type of modification Hereditary
Associated disease Parkinson's disease
Gene/locus DANi-002C: Gene GBA, Locus 1q22, Mutation
NM_001005741.2:c.1448 T>C
(NP_000148.2:p.Leu483Pro) DANi-003H: Gene GBA,
Locus 1q22, Mutation NM_001005741.2:c.1226 A>G
(NP_000148.2:p.Asn409Ser) DANi-004A: Gene PRKN,
Locus 6q26, Mutation NM_004562.2:c.758 G>A
(NP_004553.2:p.Cys253Tyr) DANi-005A: Gene LRRK2,
Locus 12q12, Mutation NM_198578.3:c.6055 G>A
(NP_940980.3:p.Gly2019Ser) and Gene GBA, Locus 1q22,
Mutation NM_001005741.2:c.1226 A>G
(NP_000148.2:p.Asn409Ser) DANi-006F: Gene GBA, Locus
1q22, Mutation NM_001005741.2:c.1448 T>C
(NP_000148.2:p.Leu483Pro) DANi-007A: Gene PINK1,
Locus 1p36.12, Mutation NM_032409.2:c.1366 C>T
(NP_115785.1:p.Gln456Ter) DANi-008F: Gene SNCA,
Locus 4q22.1, Mutation NM_000345.3:c.157 G>A
(p.Ala53Thr) DANi-009C: Gene SNCA, Locus 4q22.1,
Mutation duplication
Method of modification Not applicable
Name of transgene or r-
esistance
Not applicable
Inducible/constitutive
system
Not applicable
Date archived/stock da-
te
DANi-002C: Oct.22, 2014 DANi-003H: Dec.3, 2014 DANi-
004A: Mar.23, 2015 DANi-005A: Jan.6, 2016 DANi-006F:
Mar.19, 2015 DANi-007A: Mar.19, 2015 DANi-008F:
Mar.19, 2015 DANi-009C: Jul.9, 2015
Cell line repository/ba-
nk
https://hpscreg.eu/user/cellline/edit/DANi002-C
https://hpscreg.eu/user/cellline/edit/DANi003-H
https://hpscreg.eu/user/cellline/edit/DANi004-A
https://hpscreg.eu/user/cellline/edit/DANi005-A
https://hpscreg.eu/user/cellline/edit/DANi006-F
https://hpscreg.eu/user/cellline/edit/DANi007-A
https://hpscreg.eu/user/cellline/edit/DANi008-F
https://hpscreg.eu/user/cellline/edit/DANi009-C
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1. Resource utility
A bank of Parkinson's disease (PD) iPSC lines from a broad range of
familial PD patients can be used to study early disease mechanisms and
those involved in its progression, which may be relevant for sporadic
cases, and provide a platform for the development or stratification of
new drugs.
1.1. Resource details
Parkinson disease is the second most common neurodegenerative
disorder, which affects a broad segment of the aging population in our
society. The majority of PD cases are sporadic; however, more than 10%
of cases are hereditary (Marti et al., 2003). Hereditary cases, where a
high penetrant pathogenic variant has been identified, provide the
opportunity to investigate PD related mechanism that may also be re-
levant for sporadic cases. Induced pluripotent stem cells (iPSCs) offer
new opportunities to use these patient cells and generate specific cell
type to model PD in vitro in a human context (Soldner et al., 2011).
Establishing a bank of PD iPSC lines from a broad range of familial PD
patients will enable the analysis of patient-specific neurons from var-
ious familial PD genetic backgrounds, which can potentially uncover
disease relevant mechanisms and help accelerate the development of
new drugs.
In this paper, we report the generation of eight iPSC lines from PD
patients. Seven reprogrammed from fibroblasts with the following fa-
milial mutations: DANi-002C heterozygous for GBA c.1448 T>C
(p.Leu483Pro, previously annotated as Leu444Pro; Tsuji et al., 1987),
DANi-003H for heterozygous GBA c.1226 A>G (p.Asn409Ser, pre-
viously annotated as Asn370Ser; Tsuji et al., 1988), DANi-004A
homozygous for PRKN c.758 G>A (p.Cys253Tyr), DANi-005A di-genic
affected and heterozygous for both LRRK2 c.6055 G>A (p.Gly2019Ser)
and GBA c.1226 A>G (p.Asn409Ser), DANi-006F heterozygous for GBA
c.1448 T>C (p.Leu483Pro), DANi-007A homozygous for PINK1
c.1366C>T (p.Gln456Ter), DANi-008F, heterozygous for SNCA
c.157G>A (p.Ala53Thr), and one iPSC line DANi-009C reprogrammed
from a lymphoblast line derived from a PD patient with a duplication of
SNCA (Table 1).
The fibroblasts and lymphoblasts were reprogrammed by transfec-
tion with POU5F1, SOX2, KLF4, MYCL and LIN28 using non-integrating
episomal vectors. After 3–4 weeks, we observed cell morphological
changes. Subsequently, iPSCs clones were picked and cultured on fee-
ders for expansion and further characterization. Chromosomal analysis
from all iPSCs showed normal karyotypes 46, XX or 46, XY
(Supplementary Fig. 1A) and the familial mutations in PD-iPSCs were
confirmed (Supplementary Fig. 2). All iPSCs were alkaline phosphatase
positive (Fig. 1A) and expressed the pluripotent markers, POU5F1, and
NANOG (Fig. 1B, C). Quantitative assessment of pluripotency was de-
termined by counting the percentage of POU5F1+/DAPI and
NANOG+/DAPI cells from three different colonies for each cell line
(Supplementary Figure 1B and Supplementary Table 1).
All the iPSC lines reported in this paper were confirmed to be free
from random integration of the reprogramming plasmids, which were
analyzed by qPCR (Supplementary Fig. 1C). All iPSC lines successfully
formed embryoid bodies and at day 14 cultures contained cell types
representative of the three germ layers, indicated by positive staining
for SOX17/FOXA2 (endoderm), TBX6 (mesoderm), and TUBB3 (ecto-
derm) (Fig. 1D–F). In addition, the absence of mycoplasma for all the
lines was confirmed by PCR (Supplementary Figure 1D). Cell line
identities were confirmed to match the original donors by a genetic
profile of a set of STR loci on each cell line (Table 2).
2. Materials and methods
2.1. Reprogramming patients fibroblasts to iPSCs
Patient fibroblasts and lymphoblasts from Hertie biobank or Gaslini
biobank were expanded in RPMI media supplemented with 1% glu-
tamax, pen/strep 10,000 μg/mL (all from Life Technologies), 10% FCS
(Biowest) and FGF2 (10 ng/ml; Peprotech). For reprogramming,
100,000 fibroblast cells were seeded on 9.6 cm2 (6-well plate, Cat #
140685, ThermoFisher) pre-coated with Vitronectin XF™ (STEMCELL
Technologies) and transfected with P3 primary cell 4D-Nucleofector™ X
kit L (cat#V4XP-3012, Lonza) with a Lonza 4-D Nucleofector (program:
EN-150); using episomal vectors (1 µg each vector) pCXLE-hOCT3/4-
shp53-F, pCXLE-hSK and pCXLE-hUL (Addgene plasmid numbers:
27077, 27078, 27080) that together contained the following genes
POU5F1, SOX2, KLF4, MYCL, LIN28 and shRNA against TP53, in TeSR™-
E7™ medium (STEMCELL Technologies). The medium was changed
every 3–4 days, and after 3–4 weeks without passaging, iPSC colonies
were isolated and expanded as individual clones.
The iPSCs clones were cultured on irradiated human foreskin fi-
broblasts (HFF; ATCC CRL-2097) in KSR media consisting of DMEM/
nutrient mixture F-12, supplemented with β-mercaptoethanol 0.1mM,
non-essential amino acids (NEAA) 1%, glutamine 2mM, penicillin
25 U/ml, streptomycin 25 U/ml and knockout serum replacement 20%
(all from Life Technologies), which was further supplemented with
FGF2 (15 ng/ml; Peprotech) and Activin A (15 ng/ml; R&D systems).
All cells were cultured at 37 °C and 5% CO2. Colonies were mechani-
cally dissected every seven days and transferred to freshly prepared
HFF. Mycoplasma detection was performed by using LookOut
Mycoplasma PCR Detection Kit (Cat#MP0035, Sigma) according to
manufacturer's instructions.
2.1.1. Pluripotency markers and embryoid body formation assay
iPSCs analyzed by immunocytochemistry were first fixed in 4% PFA
at 4 °C for 10 min and washed briefly in PBS and blocked for 1 h at room
temperature (RT) with 5% donkey serum in PBT (PBS with 0.25%
triton-X) solution. Primary antibodies diluted in blocking solution were
applied at 4 °C overnight followed by washes in PBT, after which the
corresponding secondary antibodies were applied for 1 h at RT
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age at collection Ethnicity Genotype of locus Disease
DANi-002C (GBA-002-C3) Male 50 unknown Heterozygous GBA c.1448 T>C (p.L483P) Parkinson's disease
DANi-003H (GBA-003-C8) Male 56 unknown Heterozygous GBA c.1226 A>G (p.N409S) Parkinson's disease
DANi-004A (PRKN-003-C1) Female 28 unknown Homozygous PRKN c.758 G>A (p.C253Y) Parkinson's disease
DANi-005A (LRRK2-GBA-
005-C1)
Male 66 unknown Heterozygous LRRK2 c.6055 G>A (p.G2019S) and
Heterozygous GBA c.1226 A>G (p.N409S)
Parkinson's disease
DANi-006F (GBA-006-C6) Female 39 unknown Heterozygous GBA c.1448 T>C (p.L483P) Parkinson's disease
DANi-007A (PINK1-007-C1) Male 59 unknown Homozygous PINK1 c.1366 C>T (p.Q456X) Parkinson's disease
DANi-008F (SNCA-008-C6) Male 45 unknown Heterozygous SNCA c.157 G>A (p.A53T) Parkinson's disease
DANi-009C (SNCA-009-C3) Female 45 unknown SNCA duplication Parkinson's disease
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(antibodies shown in Table 3). Nuclei were counterstained with 4,6-
diamidino-2-phenylindole (DAPI; 1 μg/ml, Sigma). Positive cells for
POU5F1 and NANOG staining was counting from three different co-
lonies and data expressed as a percentage of POU5F1+/DAPI and
NANOG+/DAPI.
Alkaline phosphatase staining was performed following
manufacturer's procedure (Cat#00-0009, Stemgent).
Embryoid bodies (EBs) were generated from iPSCs by culturing
fragments in ultra-low cluster 96-well plate (Cat#3474, Corning) in
suspension and cultured in KSR media supplemented with 1.5 µM
CHIR99021 (Cat#04-0004-10, Stemgent), 40 ng/ml BMP2 (Cat#120-
02, Peprotech), and 10 ng/ml Activin A. At day 14, EBs were collected,
Fig. 1. Characterization of eight human iPSC lines generated from Parkinson's disease patients carrying familial mutations.
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fixed in 4% PFA for 20 min at 4 °C and then washed briefly in PBS, kept
in 30% sucrose overnight and embedded in Tissue-Tek OCT compound
(Labtek). Sections were cut at 10 µm on a cryostat and used for im-
munostaining (Table 3). After immunostaining, slides were mounted in
PVA-DABCO for viewing under a fluorescent microscope (ZEISS Apo-
Tome), and images captured using the ZEN software. Confocal micro-
scopy was performed using a ZEISS LSM 780 Confocal Microscope
(Fig. 1).
2.2. Genomic analysis
Karyotype analysis was performed on Q-banded metaphase spreads
that were prepared according to standard protocol at a clinical accre-
dited laboratory. Ten metaphases were counted and two analysed
according to clinical standards. Briefly, growth medium was renewed
and colcimide was added to the cultures at 0.1 µg/ml and incubated at
37 °C for 60–120 min depending on the donor. The PD iPSC cells were
harvested by trypsinization (0.025% W/V in Hanks buffered saline) at
37 °C. The trypsinization was stopped by adding serum-containing
medium. Cells were collected by centrifugation and then incubated in
hypotonic KCl 0.56% at 37 °C for 30 min in a water bath. Cells were
collected by centrifugation and resuspended in fixation buffer (1 part
glacial acetic acid and 3 parts methanol). The cells were spun down by
centrifugation and resuspended in fixative. This step was repeated once.
The resuspended cells were added dropwise to slide glasses, dried,
stained by quinacrine and mounted for fluorescence microscopy.
Genomic DNA were collected and purified using GeneJet Genomic
DNA purification kit (Cat #K0721, ThermoFisher Scientific). Familial
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal morphology Fig. 1 panel A
Phenotype Qualitative analysis by
Immunocytochemistry
Positive staining/expression of pluripotency markers: Alkaline
phosphatase (ALP), POU5F1, NANOG
Fig. 1 panel A, B, C
Quantitative analysis by
Immunocytochemistry counting
Assess% of positive cells for antigen markers. POU5F1: all above
97%, NANOG: all above 96%.
Supplementary Fig. 1 panel B,
Supplementary Table 1
Genotype Karyotype (Q-banding) and resolution 46 XY, 46 XX. Resolution 450–500 Supplementary Fig. 1 panel A
Identity STR analysis DNA Profiling Performed
10 genomic markers 100% matched between parental cells and
respective iPSCs
Available with the authors
Mutation analysis (IF
APPLICABLE)
Sequencing Heterozygous: DANi002, DANi003, DANi005, DANi006,
DANi008, DANi009.Homozygous: DANi004, DANi007.
Supplementary Fig. 2
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by PCR: Negative Supplementary Fig. 1D
Differentiation potential Embryoid body formation Embryoid bodies formation expressing endoderm markers:
SOX17/FOXA2; mesoderm marker: TBX6; ectoderm marker:
TUBB3.
Fig. 1 panel D–F.
Table 3
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-OCT3/4(C-10) 1:100 Santa Cruz Biotechnology Cat# sc-5279, RRID:AB_628051
Pluripotency Markers Mouse anti-NANOG 1:100 eBioscience Cat# 14-5768-82, RRID:AB_467572
Differentiation Markers Goat anti-SOX17 1:200 R&D Systems Cat# AF1924, RRID:AB_355060
Differentiation Markers Rabbit anti-FOXA2 1:500 Cell signaling Technology Cat#8186; RRID: AB_10891055
Differentiation Markers Goat anti-TBX6 1:100 R&D Systems Cat# AF4744 RRID:AB_2200834
Differentiation Markers Mouse anti-TUBB3 1:1000 Millipore Cat# MAB1637, RRID:AB_2210524
Secondary antibodies for IF Goat anti-mouse IgG2b Alexa 568 1:1000 ThermoFisher Scientific Cat# A21144, RRID: AB_2535780
Secondary antibodies for IF Goat anti-mouse IgG1 Alexa 488 1:1000 ThermoFisher Scientific Cat# A21121, RRID:AB_141514
Secondary antibodies for IF Donkey anti-mouse IgM Alexa 488 1:200 Jackson ImmunoResearch Cat# 715-545-020, RRID:AB_2340844
Secondary antibodies for IF Goat anti-mouse IgG3 Alexa 594 1:200 Jackson ImmunoResearch Cat# 115-585-209, RID:AB_AB_2338889
Secondary antibodies for IF Donkey anti-goat IgG (H+L) Alexa 488 1:1000 ThermoFisher Scientific Cat# A-11055, AB_2534102
Secondary antibodies for IF Donkey anti-rabbit IgG (H+L) Alexa 568 1:1000 ThermoFisher Scientific Cat# A11057, AB_2534104
Secondary antibodies for IF Donkey anti-mouse IgG (H+L) Alexa 568 1:1000 ThermoFisher Scientific Cat# A10037, AB_2534013
Primers
Target Forward/Reverse primer (5′−3′)
Episomal Plasmids (qPCR) Plasmid DNA Product size 95 AGGTCCCTCGAAGAGGTTCA/ TTCCAACGCGAGAAGGTGTT
Episomal Plasmids Template control (qPCR) Albumin Product size 73 TTTGCAGATGTCAGTGAAAGAGA/ TGGGGAGGCTATAGAAAATAAGG
Targeted mutation analysis GBA N409S Product size 497 ATCATCACGGTAAGCCACCC/ CGACAAAGTTACGCACCCAA
Targeted mutation sequencing primer GBA N409S ATCATCACGGTAAGCCACCC
Targeted mutation analysis GBA L483P Product size 1445 TTGGGTGCGTAACTTTGTCG / CTCACGCTCCCAAGACTGG
Targeted mutation sequencing GBA L483P CTGAGAGTGTGATCCTGCCAA
Targeted mutation analysis SNCA A53T Product size 486 TGTAGGCTCCAAAACCAAGG/ CTGTCCAAGGGTGTTTCCTG
Targeted mutation sequencing SNCA A53T ATGTTCTTAGAATGCTCAGTGATTG
Targeted mutation analysis PINK1 Q456X Product size 430 GAGTTCAGATTAGCCCATGG/ ATCTGTCACTGTGGCTCTGG
Targeted mutation sequencing PINK1 Q456X GAGTTCAGATTAGCCCATGG
Targeted mutation analysis PRKN C253Y Product size 239 TGCCTTTCCACACTGACAGGTACT/ TCTGTTCTTCATTAGCATTAGAGA
Targeted mutation sequencing PRKN C253Y TGCCTTTCCACACTGACAGGTACT
Targeted mutation analysis LRRK2 G2019S Product size 518 GGCAGATACCTCCACTCAGC/ TTGATTTGCCTCACAAGTGC
Targeted mutation sequencing LRRK2 G2019S GGCAGATACCTCCACTCAGC
Targeted mutation analysis (qPCR) SNCA (duplication) Product size 73 GGAACATTAACCCTACACTCGG/ GGAACCAGTGCATACCAAAAC
Targeted mutation analysis (qPCR) SNCA (duplication) Probe [6FAM]TCCCTGAAGCAACACTGCCAGAA[BHQ1]
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mutations for each of the PD iPSC lines and their parental cell lines
were validated by either standard PCR or qPCR. The standard PCR
amplification was done with Thermo Scientific™ Arktik™ Thermal
Cycler with the following program: initial denaturation at 94 °C for
30 s; 35 cycles of (94 °C for 30 s, 60 °C for 30 s, 68 °C for 30 s); final
extension at 68 °C for 5 min and hold at 15 °C. PCR products were ex-
tracted and cleaned with DNA Clean and concentrator kit (Cat#D4005,
Zymo Research) and then samples were prepared and sent to Eurofins
Genomics for Sanger sequencing using primers in Table 3. QPCR were
done with 7500 Fast Real-Time PCR system (Applied Biosystems) using
Taqman Universal Master Mix II no UNG (Cat#444040, ThermoFisher
Scientific) to confirm the mutations of SNCA duplication of the DANi-
009C and the original parental lymphoblasts. iPSC clones were tested
for random integration of episomal plasmids by qPCR with a Go-
Taq®qPCR System kit (Cat#A6001, Promega) for EBNA/OriP sequences
using primers in Table 3 and those positive for plasmid integration were
excluded. Cell line identity was performed by the Department of Mo-
lecular Medicine (MOMA) at Aarhus University Hospital with the
GenePrint® 10 system.
Acknowledgments
This study was supported by Lundbeckfonden grant no. DANDRITE-
R248-2016-2518. MC is supported by a postdoctoral fellowship from
the Lundbeckfonden grant no. R209-2015-3100. MD is a partner of
BrainStem—Stem Cell Center of Excellence in Neurology, funded by
Innovation Fund Denmark. For providing us with patient samples, we
would like to thank the Neuro-Biobank of the University of Tuebingen,
Germany (http://www.hihtuebingen.de/nd/biobank/for-researchers/).
This biobank is supported by the Hertie Institute and the DZNE. We
would also like to thank the ‘Cell Line and DNA Biobank from Patients
affected by Genetic Diseases’ (Istituto G. Gaslini) and the “Parkinson
Institute Biobank” (Milan, http://www.parkinsonbiobank.com/),
members of the Telethon Network of Genetic Biobanks (project no.
GTB12001), funded by Telethon Italy.
Supplementary materials
Supplementary material associated with this article can be found, in
the online version, at doi:10.1016/j.scr.2019.101657.
References
Marti, M.J., Tolosa, E., Campdelacreu, J., 2003. Clinical overview of the synucleino-
pathies. Mov. Disord. 18, 21–27. https://doi.org/10.1002/mds.10559.
Soldner, F., Laganiere, J., Cheng, A.W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana,
V., Golbe, L.I., Myers, R.H., Lindquist, S., Zhang, L., Guschin, D., Fong, L.K., Vu, B.J.,
Meng, X., Urnov, F.D., Rebar, E.J., Gregory, P.D., Zhang, H.S., Jaenisch, R., 2011.
Generation of isogenic pluripotent stem cells differing exclusively at two early onset
parkinson point mutations. Cell 146, 318–331. https://doi.org/10.1016/j.cell.2011.
06.019.
Tsuji, S., Choudary, P., Martin, B., Stubblefield, B., Mayor, J., Barranger, J., Ginns, E.,
1987. A mutatuion in the human glucocerebrosidase gene in neuronopathic gaucher's
disease. N. Engl. J. Med. 316, 570–575. https://doi.org/10.1056/
NEJM198703053161002.
Tsuji, S., Martin, B.M., Barranger, J.A., Stubblefield, B.K., LaMarca, M.E., Ginns, E.I.,
1988. Genetic heterogeneity in type 1 gaucher disease: multiple genotypes in
Ashkenazic and non-Ashkenazic individuals. Proc. Natl. Acad. Sci. 85, 2349–2352.
https://doi.org/10.1073/pnas.85.7.2349.
M. Chen, et al. Stem Cell Research 42 (2020) 101657
5
